ClinicalTrials.gg
RecruitingNCT07441720Updated Oct 13, 2026

Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)

A Phase 2 interventional study of umbilical cord blood in Thrombocytopenia and Cancer Treatment-induced Thrombocytopenia, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Zhejiang Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.

Planned enrollment
83rd of 96
25 · median 82
Started
2026
with 5 others
Phase 2
31 of 108
23 open now
Primary completion
2027-06
later than 32 of 44 live
Registered
97th of 108
by date

Among the 108 studies in Thrombocytopenia with a site in China, this one is the 83rd largest by planned enrollment of the 96 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 in phase 2, reaches primary completion later than 32 of the 44 other live ones, and was the 97th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Thrombocytopenia with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients. It plans to recruit subjects aged 12 to 75 years old with CTIT. The study involves intravenous infusion of umbilical cord blood, with platelet transfusion as supportive therapy if necessary. The trial consists of three phases: screening (baseline assessments and enrollment), treatment (umbilical cord blood infusion), and follow-up (blood routine tests at Days 3, 7, 14, and 28 post-treatment to record platelet counts, first response time, maximum and minimum values, and calculate efficacy rates while observing changes in thrombocytopenia grading). A total of 25 subjects will be enrolled, and they will undergo evaluation for safety and efficacy based on treatment-related adverse events, GVHD incidence, and hematological improvements.

Read the detailed description

Umbilical cord blood infusion involves cord blood-derived hematopoietic stem cells sourced from the Umbilical Cord Blood Hematopoietic Stem Cell Bank, with HLA typing 0-3/10 matched, total nucleated cells (TNC) >1×10\^7/kg, and ABO blood type identical to the recipient. Following intravenous infusion, it promotes platelet recovery by providing hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and growth factors that stimulate bone marrow progenitor cell proliferation in the in vivo environment, thereby elevating platelet levels.

The primary endpoint of this study is:

Treatment efficacy rate: Post-treatment platelet count ≥100×10\^9/L, or an increase of ≥50×10\^9/L from baseline, or an increase of ≥100% from baseline.

Secondary endpoints include:

Platelet first response time: Time to first platelet count ≥100×10\^9/L without platelet transfusion; Maximum and minimum platelet counts; Incidence of bleeding events after initial infusion; Number of platelet transfusions; Changes in thrombocytopenia grading; Treatment-related adverse events; Incidence and grading of graft-versus-host disease (GVHD).

03

Conditions studied

  • Thrombocytopenia
  • Cancer Treatment-induced Thrombocytopenia

Browse trials for

Keywords

  • Umbilical cord blood
  • Cancer treatment-induced thrombocytopenia
  • CTIT
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 12 to 75 years at the time of signing the , regardless of gender.
  2. Meets the diagnostic criteria for cancer treatment-induced thrombocytopenia (CTIT):Peripheral blood count \< 100 × 10⁹/L; Prior definite exposure to a chemotherapy agent (or tumor-targeted therapy, immunotherapy, or other anti-tumor drugs) known to cause thrombocytopenia, with gradual improvement of thrombocytopenia-related symptoms/signs or normalization of platelet count after discontinuation of the offending drug; Presence or absence of bleeding tendency, such as petechiae, purpura, unexplained epistaxis, or even severe organ/tissue hemorrhage;
  3. No significant hepatic or renal impairment: and AST ≤ 2.5 × (ULN), serum creatinine (Cr) and blood urea nitrogen (BUN) ≤ 1.25 × ULN;
  4. Performance Status (KPS) score ≥ 60 (see Appendix 1), (ECOG) performance status ≤ 2 (see Appendix 2);
  5. Estimated of more than 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Other causes of thrombocytopenia, in particular exclusion of underlying diseases or comorbidities such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenia (ITP), hypersplenism, or bone marrow infiltration by tumor cells;
  2. Use of non-anti-tumor medications known to cause thrombocytopenia (including but not limited to sulfonamides and other drugs);
  3. Pseudothrombocytopenia induced by ethylenediaminetetraacetic acid (EDTA) anticoagulant;
  4. Uncontrolled malignant tumor, hypertension, or diabetes mellitus;
  5. Active infection, including but not limited to known positivity, active or C, or syphilis;
  6. Poor compliance;
  7. Known allergy or to any component of the study intervention (umbilical cord blood or related products);
  8. Participation in another clinical trial within 1 month prior to enrollment or current participation in another clinical trial;
  9. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Umbilical Cord Blood for CTIT Treatment

    Participants receive intravenous infusion of allogeneic umbilical cord blood (HLA matching 0-3/10 loci, total nucleated cells \[TNC\] \>1×10\^7/kg, ABO blood type identical/compatible). Infusions are administered 2-4 times as needed based on clinical response. Platelet transfusions are permitted as supportive therapy if required. The intervention aims to promote platelet recovery through hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and associated growth factors in patients with cancer treatment-induced thrombocytopenia (CTIT). No comparator or control arm is included in this single-arm design.

    Other: umbilical cord blood

Interventions

  • Otherumbilical cord blood

    Umbilical cord blood will be selected from a public cord blood bank, requiring an HLA match of 0-3/10, a total nucleated cell (TNC) count \>1 × 10⁷/kg, and ABO blood type identical to the recipient. The umbilical cord blood will be intravenously infused into the subject within 30 minutes.

06

What researchers measure

Primary outcomes

  1. Treatment efficacy rate

    Treatment efficacy rate: Post-treatment platelet count ≥100×10\^9/L, or an increase of ≥50×10\^9/L from baseline, or an increase of ≥100% from baseline.

    Time frame: 28 days post-infusion

  2. Treatment-related adverse events

    Time frame: 28 days post-infusion

Secondary outcomes

  1. (1)Platelet first response time and maximum and minimum platelet counts;

    Platelet first response time: Time to first platelet count ≥100×10\^9/L without platelet transfusion and maximum and minimum platelet counts;

    Time frame: 28days post-infusion

  2. Incidence of bleeding events after initial infusion;

    Time frame: 28 days post-infusion

  3. Number of platelet transfusions;

    Time frame: 28 days post-infusion

  4. Changes in thrombocytopenia grading;

    Time frame: 28 days post-infusion

  5. Incidence and grading of graft-versus-host disease (GVHD)

    Time frame: 100 days post-infusion

07

Study locations

1 of 1 sites recruiting
  • Department of Hematology, Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 44 non-industry phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 83. This study's planned 16 months is below that.

Counting every sponsor, half of 54 studies reached it within 36 months; a quarter within 28 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 2, 2026
StartActual
Feb 28, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAged 12 to 6575 years at the time of signing the informed consent, regardless of gender.
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAged 12 to 6575 years at the time of signing the informed consent, regardless of gender.
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07441720
Responsible party
TanYamin (Chief Physician, Zhejiang Cancer Hospital) — Principal investigator
First posted
Mar 2, 2026
Start date
Feb 28, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Xiaolin Yuan
Contact
yuanxiaolinhaha@163.com
+86 057188122153

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion